NO20053986L - Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1. - Google Patents

Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.

Info

Publication number
NO20053986L
NO20053986L NO20053986A NO20053986A NO20053986L NO 20053986 L NO20053986 L NO 20053986L NO 20053986 A NO20053986 A NO 20053986A NO 20053986 A NO20053986 A NO 20053986A NO 20053986 L NO20053986 L NO 20053986L
Authority
NO
Norway
Prior art keywords
polypeptides
igsf9
liv
methods
compositions
Prior art date
Application number
NO20053986A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053986D0 (no
Inventor
Robert J Peach
Karen Mclachlan
Scott Glaser
Tony Rowe
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20053986D0 publication Critical patent/NO20053986D0/no
Publication of NO20053986L publication Critical patent/NO20053986L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20053986A 2003-01-27 2005-08-26 Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1. NO20053986L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44253503P 2003-01-27 2003-01-27
PCT/US2004/002044 WO2004066933A2 (en) 2003-01-27 2004-01-27 Compositions and methods for treating cancer using igsf9 and liv-1

Publications (2)

Publication Number Publication Date
NO20053986D0 NO20053986D0 (no) 2005-08-26
NO20053986L true NO20053986L (no) 2005-10-27

Family

ID=32825236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053986A NO20053986L (no) 2003-01-27 2005-08-26 Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.

Country Status (16)

Country Link
US (2) US20040258616A1 (pl)
EP (1) EP1596806A4 (pl)
JP (1) JP2006520194A (pl)
KR (1) KR20050102627A (pl)
CN (1) CN1849337A (pl)
AU (1) AU2004207538A1 (pl)
BR (1) BRPI0407031A (pl)
CA (1) CA2514062A1 (pl)
EA (1) EA200501197A1 (pl)
IS (1) IS7960A (pl)
MX (1) MXPA05007940A (pl)
NO (1) NO20053986L (pl)
PL (1) PL379264A1 (pl)
RS (1) RS20050577A (pl)
WO (1) WO2004066933A2 (pl)
ZA (1) ZA200506671B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
US20080070836A1 (en) * 2003-12-26 2008-03-20 Toshio Hirano Emt-Inducing Agents
WO2006014999A2 (en) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
TW200813231A (en) * 2006-04-13 2008-03-16 Novartis Vaccines & Diagnostic Methods of treating, diagnosing or detecting cancer
KR20110091423A (ko) * 2010-02-05 2011-08-11 국립암센터 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물
NZ611468A (en) * 2010-12-06 2015-06-26 Seattle Genetics Inc Humanized antibodies to liv-1 and use of same to treat cancer
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
JP7265788B2 (ja) * 2017-05-09 2023-04-27 シアノ バイオテック ゲーエムベーハー 修飾ミクロシスチンおよびノジュラリン
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
WO2021201571A1 (ko) * 2020-03-31 2021-10-07 웰마커바이오 주식회사 Igsf1 에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
CN116082503B (zh) * 2022-08-19 2023-08-04 滨州医学院 一种靶向人igsf9的单克隆抗体及其应用
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) * 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) * 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
PL174721B1 (pl) * 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2149326C (en) * 1992-11-13 2007-04-17 Mitchell E. Reff Fully impaired consensus kozak sequences for mammalian expression
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
KR20020073181A (ko) * 2000-01-25 2002-09-19 제넨테크, 인크. Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
AU2001290548A1 (en) * 2000-09-11 2002-03-26 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
EP1596806A2 (en) 2005-11-23
WO2004066933A3 (en) 2006-03-02
US20040258616A1 (en) 2004-12-23
AU2004207538A1 (en) 2004-08-12
WO2004066933A2 (en) 2004-08-12
PL379264A1 (pl) 2006-08-07
IS7960A (is) 2005-07-27
MXPA05007940A (es) 2007-06-14
KR20050102627A (ko) 2005-10-26
EA200501197A1 (ru) 2006-04-28
EP1596806A4 (en) 2007-08-29
CA2514062A1 (en) 2004-08-12
US20070071674A1 (en) 2007-03-29
ZA200506671B (en) 2006-09-27
BRPI0407031A (pt) 2006-01-17
NO20053986D0 (no) 2005-08-26
JP2006520194A (ja) 2006-09-07
RS20050577A (en) 2007-09-21
CN1849337A (zh) 2006-10-18

Similar Documents

Publication Publication Date Title
NO20053986L (no) Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.
CY1119127T1 (el) Επιτοποι σκληροστινης
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2003034903A3 (en) Psma antibodies and protein multimers
NO347649B1 (no) Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
DK1844072T3 (da) MHC-oligomer og fremgangsmåde til fremstilling deraf
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
DE60028970D1 (de) An her2 bindende peptidverbindungen
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
MY137552A (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
NO20091736L (no) IL-17-reseptor A-antigenbindende proteiner
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
WO2006087637A3 (en) Anti her2/neu antibody
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
EP2287194A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MXPA05006034A (es) Proteina de duplicacion.
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
WO2004069860A3 (en) Isg15-conjugated proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application